Literature DB >> 25592466

Prostate cancer: The main risk and protective factors-Epigenetic modifications.

Mawussi Adjakly1, Marjolaine Ngollo1, Aslihan Dagdemir1, Gaëlle Judes1, Amaury Pajon1, Seher Karsli-Ceppioglu2, Frédérique Penault-Llorca3, Jean-Paul Boiteux4, Yves-Jean Bignon5, Laurent Guy6, Dominique Bernard-Gallon1.   

Abstract

With 13 million new cases worldwide every year, prostate cancer is as a very real public health concern. Prostate cancer is common in over-50s men and the sixth-leading cause of cancer-related death in men worldwide. Like all cancers, prostate cancer is multifactorial - there are non-modifiable risk factors like heredity, ethnicity and geographic location, but also modifiable risk factors such as diet. Diet-cancer linkages have risen to prominence in the last few years, with accruing epidemiological data pointing to between-population incidence differentials in numerous cancers. Indeed, there are correlations between fat-rich diet and risk of hormone-dependent cancers like prostate cancer and breast cancer. Diet is a risk factor for prostate cancer, but certain micronutrients in specific diets are considered protective factors against prostate cancer. Examples include tomato lycopene, green tea epigallocatechin gallate, and soy phytoestrogens. These micronutrients are thought to exert cancer-protective effects via anti-oxidant pathways and inhibition of cell proliferation. Here, we focus in on the effects of phytoestrogens, and chiefly genistein and daidzein, which are the best-researched to date. Soy phytoestrogens are nonsteroid molecules whose structural similarity lends them the ability to mimic the effects of 17ß-estradiol. On top of anti-oxidant effects, there is evidence that soy phytoestrogens can modulate the epigenetic modifications found in prostate cancer. We also studied the impact of phytoestrogens on epigenetic modifications in prostate cancer, with special focus on DNA methylation, miRNA-mediated regulation and histone modifications.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alimentation; Cancer de la prostate; Diet; Epigenetics; Phytoestrogens; Prostate cancer; Risk factors; Épigénétique

Mesh:

Substances:

Year:  2015        PMID: 25592466     DOI: 10.1016/j.ando.2014.09.001

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  12 in total

1.  MiR181c inhibits ovarian cancer metastasis and progression by targeting PRKCD expression.

Authors:  Lijuan Yao; Li Wang; Fengxia Li; Xihai Gao; Xuegong Wei; Zhihui Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  STK10 knockout inhibits cell migration and promotes cell proliferation via modulating the activity of ERM and p38 MAPK in prostate cancer cells.

Authors:  Lu Zhang; Shun-Yuan Lu; Rui Guo; Jin-Xia Ma; Ling-Yun Tang; Jin-Jin Wang; Chun-Ling Shen; Li-Ming Lu; Jie Liu; Zhu-Gang Wang; Hong-Xin Zhang
Journal:  Exp Ther Med       Date:  2021-06-08       Impact factor: 2.447

3.  MiR-215, an activator of the CTNNBIP1/β-catenin pathway, is a marker of poor prognosis in human glioma.

Authors:  Yong-Qing Tong; Bei Liu; Hong-Yun Zheng; Jian Gu; Hang Liu; Feng Li; Bi-Hua Tan; Melanie Hartman; Chunhua Song; Yan Li
Journal:  Oncotarget       Date:  2015-09-22

Review 4.  Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.

Authors:  Alessandra Bosutti; Fabrizio Zanconati; Gabriele Grassi; Barbara Dapas; Sabina Passamonti; Bruna Scaggiante
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

5.  Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.

Authors:  Ying-Li Lin; Qiu-Kui Deng; Yu-Hao Wang; Xing-Li Fu; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2015-12-19

6.  A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2.

Authors:  Marine Daures; Mouhamed Idrissou; Gaëlle Judes; Khaldoun Rifaï; Frédérique Penault-Llorca; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  Oncotarget       Date:  2018-05-04

Review 7.  Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives.

Authors:  Bagora Bayala; Abdou Azaque Zoure; Silvère Baron; Cyrille de Joussineau; Jacques Simpore; Jean-Marc A Lobaccaro
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

8.  TRIM66 promotes malignant progression of prostate carcinoma through the JAK/STAT pathway.

Authors:  Hongwen Cao; Renjie Gao; Lei Chen; Yigeng Feng
Journal:  FEBS Open Bio       Date:  2020-03-03       Impact factor: 2.693

Review 9.  The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer.

Authors:  Christian Bronner; Marc Mousli; Waseem Ashraf; Abdulkhaleg Ibrahim; Mahmoud Alhosin; Liliyana Zaayter; Khalid Ouararhni; Christophe Papin; Tanveer Ahmad; Ali Hamiche; Yves Mély
Journal:  Oncotarget       Date:  2017-04-24

Review 10.  Long Non-Coding RNAs at the Chromosomal Risk Loci Identified by Prostate and Breast Cancer GWAS.

Authors:  Panchadsaram Janaththani; Sri Lakshmi Srinivasan; Jyotsna Batra
Journal:  Genes (Basel)       Date:  2021-12-20       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.